Advances in Targeting ACE2 for Developing COVID-19 Therapeutics
Author:
Funder
American Heart Association
Publisher
Springer Science and Business Media LLC
Subject
Biomedical Engineering
Link
https://link.springer.com/content/pdf/10.1007/s10439-022-03094-w.pdf
Reference100 articles.
1. Coronavirus (COVID-19) Update. FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19. US Food and Drug Administration, 2020.
2. Abd El-Aziz, T. M., A. Al-Sabi, and J. D. Stockand. Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19. Signal Transduc. Target Therapy. 5:258–258, 2020
3. Abdelrahman, Z., M. Li, and X. Wang. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses. Front. Immunol. 11:552909–552909, 2020
4. Abu-Izneid, T., N. AlHajri, A. M. Ibrahim, M. N. Javed, K. M. Salem, F. H. Pottoo, and M. A. Kamal. Micro-RNAs in the regulation of immune response against SARS CoV-2 and other viral infections. J. Adv. Res. 30:133–145, 2021
5. Aguiar, J. A., B. J. Tremblay, M. J. Mansfield, O. Woody, B. Lobb, A. Banerjee, A. Chandiramohan, N. Tiessen, Q. Cao, and A. Dvorkin-Gheva. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. Eur. Respir. J. 56:270, 2020
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development of Novel Peptide Inhibitors Adapted to the Surface Property and Morphology of S Protein RBD;International Journal of Peptide Research and Therapeutics;2024-08-05
2. A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management;Current Topics in Medicinal Chemistry;2024-08
3. Mendelian randomization supports causality between COVID-19 and glaucoma;Medicine;2024-06-14
4. Delay induced stability switch in a mathematical model of CD8 T-cell response to SARS-CoV-2 mediated by receptor ACE2;Chaos: An Interdisciplinary Journal of Nonlinear Science;2024-04-01
5. Conversion of Host Cell Receptor into Virus Destructor by Immunodisc to Neutralize Diverse SARS‐CoV‐2 Variants;Advanced Healthcare Materials;2024-02-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3